Patents by Inventor Christopher S. Burgey
Christopher S. Burgey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11802122Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: GrantFiled: June 15, 2021Date of Patent: October 31, 2023Assignee: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason M. Cox, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Akshay A. Shah, Michael David VanHeyst, Zhe Wu
-
Publication number: 20230312528Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: June 5, 2023Publication date: October 5, 2023Applicant: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason M. Cox, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Akshay A. Shah, Michael David VanHeyst, Zhe Wu
-
Publication number: 20230227441Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: June 14, 2021Publication date: July 20, 2023Applicant: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason Michael Cox, Deodial Guy Guiadeen, III, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James T. Olsen, James J. Perkins, Jeffrey W. Schubert, Akshay A. Shah, Shawn J. Stachel, Michael David VanHeyst, Zhe Wu
-
Publication number: 20220289710Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: May 24, 2022Publication date: September 15, 2022Applicant: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L.G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Patent number: 11377438Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: GrantFiled: October 31, 2019Date of Patent: July 5, 2022Assignee: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Publication number: 20210403457Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: June 15, 2021Publication date: December 30, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason M. Cox, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Akshay A. Shah, Michael David VanHeyst, Zhe Wu
-
Publication number: 20210387966Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: October 31, 2019Publication date: December 16, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Patent number: 10968210Abstract: Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.Type: GrantFiled: November 13, 2017Date of Patent: April 6, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Anthony J. Roecker, Tianying Jian, Gang Zhou, Liangqin Guo, Walter Won, Ting Zhang, Rajan Anand, John E. Stelmach, Deping Wang, Ronald M. Kim, Mark E. Layton, Christopher S. Burgey, Philippe G. Nantermet
-
Publication number: 20200140411Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: October 31, 2019Publication date: May 7, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L. G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Publication number: 20200131167Abstract: Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.Type: ApplicationFiled: November 13, 2017Publication date: April 30, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Anthony J. Roecker, Tianying Jian, Gang Zhou, Liangqin Guo, Walter Won, Ting Zhang, Rajan Anand, John E. Stelmach, Deping Wang, Ronald M. Kim, Mark E. Layton, Christopher S. Burgey, Philippe G. Nantermet
-
Patent number: 10004740Abstract: Compounds of Formula I are described: wherein R1 and R2 are defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: March 27, 2015Date of Patent: June 26, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Jeffrey F. Fritzen, Jaume Balsells, Mehul Patel
-
Publication number: 20170173015Abstract: Compounds of Formula I are described: wherein R1 and R2 are defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: March 27, 2015Publication date: June 22, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Jeffrey F. Fritzen, Jaume Balsells, Mehul Patel
-
Patent number: 9238647Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: GrantFiled: March 15, 2010Date of Patent: January 19, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Zhengwu J. Deng, Diem Nguyen, Daniel V. Paone, Craig M. Potteiger, Shaun R. Stauffer, Carolyn Segerdell, Ashley Nomland, John J. Lim
-
Patent number: 9067941Abstract: The present invention is directed to fused heterocyclic azaindane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: December 16, 2011Date of Patent: June 30, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Anthony Ginnetti, Ashley Nomland, Daniel V. Paone
-
Patent number: 8946231Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: GrantFiled: March 15, 2010Date of Patent: February 3, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Craig M. Potteiger
-
Patent number: 8895572Abstract: The present invention is directed to fused heterocyclic indane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: December 16, 2011Date of Patent: November 25, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Anthony Ginnetti, Daniel V. Paone
-
Patent number: 8598209Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: GrantFiled: October 21, 2009Date of Patent: December 3, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Zhengwu J. Deng, Diem N. Nguyen, Daniel V. Paone, Anthony W. Shaw, Anthony Ginnetti
-
Patent number: 8569512Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: GrantFiled: March 15, 2010Date of Patent: October 29, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher S. Burgey, Brendan M. Crowley, Zhengwu J. Deng, Daniel V. Paone, Craig M. Potteiger
-
Publication number: 20130267541Abstract: The present invention is directed to fused heterocyclic azaindane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: ApplicationFiled: December 16, 2011Publication date: October 10, 2013Inventors: Christopher S. Burgey, Anthony Ginnetti, Ashley Nomland, Daniel V. Paone
-
Publication number: 20130261138Abstract: The present invention is directed to fused heterocyclic indane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: ApplicationFiled: December 16, 2011Publication date: October 3, 2013Inventors: Christopher S. Burgey, Anthony Ginnetti, Daniel V. Paone